- Home
- PTY vs DNLI Comparison
PTY vs DNLI Comparison
Compare PTY & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTY
- DNLI
- Stock Information
- Founded
- PTY 2002
- DNLI 2013
- Country
- PTY United States
- DNLI United States
- Employees
- PTY N/A
- DNLI N/A
- Industry
- PTY Investment Managers
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTY Finance
- DNLI Health Care
- Exchange
- PTY Nasdaq
- DNLI Nasdaq
- Market Cap
- PTY 2.6B
- DNLI 2.1B
- IPO Year
- PTY N/A
- DNLI 2017
- Fundamental
- Price
- PTY $13.98
- DNLI $13.44
- Analyst Decision
- PTY
- DNLI Strong Buy
- Analyst Count
- PTY 0
- DNLI 15
- Target Price
- PTY N/A
- DNLI $33.85
- AVG Volume (30 Days)
- PTY 550.4K
- DNLI 1.4M
- Earning Date
- PTY 01-01-0001
- DNLI 08-12-2025
- Dividend Yield
- PTY 9.65%
- DNLI N/A
- EPS Growth
- PTY N/A
- DNLI N/A
- EPS
- PTY N/A
- DNLI N/A
- Revenue
- PTY N/A
- DNLI N/A
- Revenue This Year
- PTY N/A
- DNLI N/A
- Revenue Next Year
- PTY N/A
- DNLI $323.34
- P/E Ratio
- PTY N/A
- DNLI N/A
- Revenue Growth
- PTY N/A
- DNLI N/A
- 52 Week Low
- PTY $11.92
- DNLI $10.57
- 52 Week High
- PTY $14.88
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- PTY 69.25
- DNLI 41.75
- Support Level
- PTY $13.73
- DNLI $13.52
- Resistance Level
- PTY $13.95
- DNLI $14.71
- Average True Range (ATR)
- PTY 0.06
- DNLI 0.65
- MACD
- PTY 0.01
- DNLI -0.08
- Stochastic Oscillator
- PTY 90.74
- DNLI 10.00
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.